GlassScriptPhysician profile
Sweekriti Adhikari
NPI 1568723716
$7,234.62
in general payments reported to CMS, 2019-2025
62 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $498 · 2021: $467 · 2022: $769 · 2023: $1,039 · 2024: $1,373 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $544.92 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $514.35 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $488.20 | 2019-2025 | |
| Pfizer INC. | $458.03 | 2019-2025 | |
| Amgen INC. | $398.79 | 2019-2023 | Kyprolis, Lumakras |
| Celgene Corporation | $368.83 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $356.48 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $275.17 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Janssen Biotech, INC. | $249.91 | 2021-2025 | Tecvayli, Talvey, Rybrevant |
| Gilead Sciences, INC. | $222.03 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $219.58 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Exelixis INC. | $196.22 | 2019-2025 | Cabometyx |
| Abbvie INC. | $189.21 | 2019-2025 | |
| Eisai INC. | $158.81 | 2019-2025 | |
| Genzyme Corporation | $155.18 | 2019-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $149.64 | 2020-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $136.22 | 2019-2025 | |
| Incyte Corporation | $136.22 | 2019-2025 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $131.97 | 2019-2025 | |
| Puma Biotechnology, INC. | $129.44 | 2019 | |
| Astellas Pharma US INC | $112.56 | 2019-2025 | Xospata, Vyloy, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $100.59 | 2019-2020 | |
| Beigene USA, INC. | $100.56 | 2020-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $98.29 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Rigel Pharmaceuticals, INC. | $85.88 | 2019-2024 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $70.19 | 2020-2024 | Columvi, Lunsumio, Polivy |
| Ipsen Biopharmaceuticals, INC | $64.87 | 2019-2025 | Somatuline Depot, Onivyde |
| Servier Pharmaceuticals LLC | $64.31 | 2024-2025 | |
| Springworks Therapeutics, INC. | $64.07 | 2024-2025 | Ogsiveo |
| Sobi, INC | $63.37 | 2022-2024 | |
| Adc Therapeutics America, INC. | $61.01 | 2022-2024 | |
| Lilly USA, LLC | $59.79 | 2019-2023 | Jaypirca, Verzenio |
| Array Biopharma INC | $58.61 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Beone Medicines USA, INC. | $53.78 | 2025 | Brukinsa |
| Geron Corporation | $47.62 | 2024-2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $44.89 | 2023-2025 | Monoferric |
| Foundation Medicine, INC. | $41.50 | 2023 | |
| Seagen INC. | $36.65 | 2023 | Tukysa, Adcetris |
| Clovis Oncology, INC. | $36.20 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $34.66 | 2024-2025 | Libtayo |
| Alnylam Pharmaceuticals INC. | $34.58 | 2022-2024 | Givlaari |
| Taiho Oncology, INC. | $33.49 | 2019-2023 | |
| Mirati Therapeutics, INC. | $31.43 | 2023 | Krazati |
| Tesaro, INC. | $30.04 | 2019 | |
| Emd Serono, INC. | $29.98 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $27.17 | 2021-2023 | Xpovio |
| Cti Biopharma Corp. | $25.28 | 2022-2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $24.97 | 2023 | Fotivda |
| Kyowa Kirin, INC. | $19.80 | 2019 | |
| Veracyte, INC. | $19.35 | 2024 | |
| Genmab U.S., INC. | $18.85 | 2024 | Tivdak |
| Cumberland Pharmaceuticals, INC. | $18.74 | 2025 | Sancuso |
| Sun Pharmaceutical Industries INC. | $16.88 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.23 | 2020 | |
| Epizyme, INC. | $15.22 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.10 | 2024 | Vivimusta |
| Blueprint Medicines Corporation | $14.78 | 2024 | Ayvakit |
| Eusa Pharma (US) LLC | $13.39 | 2019 | |
| Pharmaessentia USA Corporation | $12.99 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.82 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.69 | 2019 | |
| Verastem, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sweekriti Adhikari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.